Contieri R, Mollica V, Shariat SF, Pradere B, et al. Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann Oncol 2026 Jan 13:S0923-7534(26)00012-8. doi: 10.1016/j.annonc.2026.
PMID: 41539604